Compare PAGS & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAGS | IMNM |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 2017 | 2020 |
| Metric | PAGS | IMNM |
|---|---|---|
| Price | $9.25 | $23.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $12.00 | ★ $32.80 |
| AVG Volume (30 Days) | ★ 3.3M | 1.8M |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.42% | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,941,000.00 |
| Revenue This Year | $11.07 | N/A |
| Revenue Next Year | $7.26 | $1,127.34 |
| P/E Ratio | $7.74 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.74 | $7.96 |
| 52 Week High | $12.32 | $27.65 |
| Indicator | PAGS | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 56.29 | 63.89 |
| Support Level | $9.21 | $19.28 |
| Resistance Level | $9.43 | $25.10 |
| Average True Range (ATR) | 0.29 | 1.27 |
| MACD | 0.05 | 0.51 |
| Stochastic Oscillator | 81.41 | 72.67 |
PagSeguro Digital Ltd is a Brazilian-based company that acts as a provider of financial technology solutions focused on Micro-Merchants, Small Companies and Medium-Sized Companies (SMEs), in Brazil. The company provides a range of solutions and tools such as cash-in and cash-out options and provides access to working capital to help to manage its cash flow. It delivers an end-to-end digital ecosystem to address day-to-day financial needs, including receiving and spending funds and managing and growing businesses for clients. The company also offers the Free PagSeguro Digital Account delivering Cash-In Solutions, Online and In-Person Payment Tools, Online Payment Tools; and Web Check Outs offer tokenization, handling of shipping information, and others.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.